Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life

Esther N. Oliva, Francesco Nobile, Giuliana Alimena, Giorgina Specchia, Marco Danova, Bianca Rovati, Francesca Ronco, Stefana Impera, Antonio Risitano, Caterina Alati, Massimo Breccia, Ida Carmosino, Iolanda Vincelli, Roberto Latagliata

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 μg weekly for 24 weeks. The dose was increased to 300 μg weekly in non-responsive patients. During treatment, 10/17 (59) transfusion-dependent (TD) and 13/23 (56) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2±0.9g/dL to 10.3±1.4g/dL by 24 weeks (p0.004). The mean response duration was 22 weeks (95 CI: 19.724.0) in TF patients compared with 15.1 weeks (95 CI: 13.317.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p0.007) and CD34 cells (p0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined.

Original languageEnglish
Pages (from-to)1007-1014
Number of pages8
JournalLeukemia and Lymphoma
Volume51
Issue number6
DOIs
Publication statusPublished - 2010

Fingerprint

Myelodysplastic Syndromes
Anemia
Quality of Life
Therapeutics
Safety
Darbepoetin alfa
Stem Cells

Keywords

  • Anemia
  • Apoptosis
  • Darbepoetin alfa
  • Hemoglobin
  • Myelodysplastic syndromes
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes : Efficacy and quality of life. / Oliva, Esther N.; Nobile, Francesco; Alimena, Giuliana; Specchia, Giorgina; Danova, Marco; Rovati, Bianca; Ronco, Francesca; Impera, Stefana; Risitano, Antonio; Alati, Caterina; Breccia, Massimo; Carmosino, Ida; Vincelli, Iolanda; Latagliata, Roberto.

In: Leukemia and Lymphoma, Vol. 51, No. 6, 2010, p. 1007-1014.

Research output: Contribution to journalArticle

Oliva, EN, Nobile, F, Alimena, G, Specchia, G, Danova, M, Rovati, B, Ronco, F, Impera, S, Risitano, A, Alati, C, Breccia, M, Carmosino, I, Vincelli, I & Latagliata, R 2010, 'Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life', Leukemia and Lymphoma, vol. 51, no. 6, pp. 1007-1014. https://doi.org/10.3109/10428191003728610
Oliva, Esther N. ; Nobile, Francesco ; Alimena, Giuliana ; Specchia, Giorgina ; Danova, Marco ; Rovati, Bianca ; Ronco, Francesca ; Impera, Stefana ; Risitano, Antonio ; Alati, Caterina ; Breccia, Massimo ; Carmosino, Ida ; Vincelli, Iolanda ; Latagliata, Roberto. / Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes : Efficacy and quality of life. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 6. pp. 1007-1014.
@article{ff527c75878446ca9db94691b99a01d3,
title = "Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life",
abstract = "To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 μg weekly for 24 weeks. The dose was increased to 300 μg weekly in non-responsive patients. During treatment, 10/17 (59) transfusion-dependent (TD) and 13/23 (56) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2±0.9g/dL to 10.3±1.4g/dL by 24 weeks (p0.004). The mean response duration was 22 weeks (95 CI: 19.724.0) in TF patients compared with 15.1 weeks (95 CI: 13.317.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p0.007) and CD34 cells (p0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined.",
keywords = "Anemia, Apoptosis, Darbepoetin alfa, Hemoglobin, Myelodysplastic syndromes, Quality of life",
author = "Oliva, {Esther N.} and Francesco Nobile and Giuliana Alimena and Giorgina Specchia and Marco Danova and Bianca Rovati and Francesca Ronco and Stefana Impera and Antonio Risitano and Caterina Alati and Massimo Breccia and Ida Carmosino and Iolanda Vincelli and Roberto Latagliata",
year = "2010",
doi = "10.3109/10428191003728610",
language = "English",
volume = "51",
pages = "1007--1014",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes

T2 - Efficacy and quality of life

AU - Oliva, Esther N.

AU - Nobile, Francesco

AU - Alimena, Giuliana

AU - Specchia, Giorgina

AU - Danova, Marco

AU - Rovati, Bianca

AU - Ronco, Francesca

AU - Impera, Stefana

AU - Risitano, Antonio

AU - Alati, Caterina

AU - Breccia, Massimo

AU - Carmosino, Ida

AU - Vincelli, Iolanda

AU - Latagliata, Roberto

PY - 2010

Y1 - 2010

N2 - To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 μg weekly for 24 weeks. The dose was increased to 300 μg weekly in non-responsive patients. During treatment, 10/17 (59) transfusion-dependent (TD) and 13/23 (56) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2±0.9g/dL to 10.3±1.4g/dL by 24 weeks (p0.004). The mean response duration was 22 weeks (95 CI: 19.724.0) in TF patients compared with 15.1 weeks (95 CI: 13.317.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p0.007) and CD34 cells (p0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined.

AB - To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 μg weekly for 24 weeks. The dose was increased to 300 μg weekly in non-responsive patients. During treatment, 10/17 (59) transfusion-dependent (TD) and 13/23 (56) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2±0.9g/dL to 10.3±1.4g/dL by 24 weeks (p0.004). The mean response duration was 22 weeks (95 CI: 19.724.0) in TF patients compared with 15.1 weeks (95 CI: 13.317.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p0.007) and CD34 cells (p0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined.

KW - Anemia

KW - Apoptosis

KW - Darbepoetin alfa

KW - Hemoglobin

KW - Myelodysplastic syndromes

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=77953527063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953527063&partnerID=8YFLogxK

U2 - 10.3109/10428191003728610

DO - 10.3109/10428191003728610

M3 - Article

C2 - 20367566

AN - SCOPUS:77953527063

VL - 51

SP - 1007

EP - 1014

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -